The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Non Platinum Metal Complexes as Anti‐cancer Drugs
Abstract
The development of metal complexes with platinum central atoms such as cisplatin or carboplatin had an enormous impact on current cancer chemotherapy. However, the spectrum of cancers that can be treated with platinum agents is narrow and treatment efficacy suffers from side effects and resistance phenomena. These unresolved problems in platinum‐based anti‐cancer therapy have stimulated increased research efforts in the search for novel non platinum‐containing metal species as cytostatic agents. Preclinical and clinical investigations showed that the development of new metal agents with modes of action different from cisplatin is possible. Thus, complexes with iron, cobalt, or gold central atoms have shown promising results in preclinical studies and compounds with titanium, ruthenium, or gallium central atoms have already been evaluated in phase I and phase II trials. This review covers some relevant examples of preclinical and clinical research on novel non platinum metal complexes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Hartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B., Zorbas, H., & Keppler, B. K. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.02.013 · Cited by 956
Rademaker-Lakhai, J. M., van den Bongard, D., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0746 · Cited by 833
In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
Scolaro, C., Bergamo, A., Brescacín, L., Delfino, R., Cocchietto, M., Laurenczy, G., Geldbach, T. J., Sava, G., & Dyson, P. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050015d · Cited by 784
Metal-based antitumour drugs in the post genomic era
Dyson, P. J., & Sava, G. (2006) · Dalton Transactions · doi:10.1039/b601840h · Cited by 771
Galanski, M. S., Jakupec, M. A., & Keppler, B. K. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054637626 · Cited by 721
Ruthenium metallopharmaceuticals
Clarke, M. J. (2003) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00312-0 · Cited by 687
Timerbaev, A. R., Hartinger, C. G., Aleksenko, S. S., & Keppler, B. K. (2006) · Chemical Reviews · doi:10.1021/cr040704h · Cited by 614
Evangelou, A. M. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00221-9 · Cited by 612
Ruthenium Complexes as Anticancer Agents
Kostova, I. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776360941 · Cited by 566
Human Placenta Thioredoxin Reductase
Gromer, S., Arscott, L. D., Williams, C. H., Schirmer, R. H., & Becker, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20096 · Cited by 536
Ruthenium Antimetastatic Agents
Alessio, E., Mestroni, G., Bergamo, A., & Sava, G. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043387421 · Cited by 479
Mechanisms of Therapeutic Activity for Gallium
Bernstein, L. R. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01383-8 · Cited by 446
The therapeutic application of lanthanides
Fricker, S. P. (2006) · Chemical Society Reviews · doi:10.1039/b509608c · Cited by 444
Thioredoxin reductase as a pathophysiological factor and drug target
Becker, K., Gromer, S., Schirmer, R. H., & Müller, S. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01703.x · Cited by 388
Ronconi, L., Marzano, C., Zanello, P., Corsini, M., Miolo, G., Maccà, C., Trevisan, A., & Fregona, D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0509288 · Cited by 314
Mirabelli, C. K., Johnson, R. K., Sung, C. M., Faucette, L. F., Muirhead, K. A., & Crooke, S. T. (1985) · PubMed · Cited by 295
Collery, P., Keppler, B., Madoulet, C., & Desoize, B. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00225-6 · Cited by 269
On the mechanism of the antitumor activity of ferrocenium derivatives
Osella, D., Ferrali, M., Zanello, P., Laschi, F., Fontani, M., Nervi, C., & Cavigiolio, G. (2000) · Inorganica Chimica Acta · doi:10.1016/s0020-1693(00)00147-x · Cited by 266
Complexes of metals other than platinum as antitumour agents
K�pf-Maier, P. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00193472 · Cited by 261
Ferricenium complexes: A new type of water-soluble antitumor agent
K�pf-Maier, P., K�pf, H., & Neuse, E. W. (1984) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00390468 · Cited by 248
McKeage, M. J., Maharaj, L., & Berners-Price, S. J. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00048-6 · Cited by 243
Antitumour Metallocenes: Structure-Activity Studies and Interactions with Biomolecules.
Harding, M., & Mokdsi, G. (2000) · Current Medicinal Chemistry · doi:10.2174/0929867003374066 · Cited by 233
Thioredoxin Reductase Activity Is Decreased by Selenium Deficiency
Hill, K. E., McCollum, G. W., Boeglin, M. E., & Burk, R. F. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6618 · Cited by 215
Phase II Clinical Trial of Titanocene Dichloride in Patients with Metastatic Breast Cancer
Kröger, N., Kleeberg, U. R., Mross, K., Edler, L., & Hossfeld, D. K. (2000) · Oncology Research and Treatment · doi:10.1159/000027075 · Cited by 209
Ott, I., Schmidt, K., Kircher, B., Schumacher, P., Wiglenda, T., & Gust, R. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049326z · Cited by 207
Self-citationPongratz, M., Schluga, P., Jakupec, M. A., Arion, V. B., Hartinger, C. G., Allmaier, G., & Keppler, B. K. (2004) · Journal of Analytical Atomic Spectrometry · doi:10.1039/b309160k · Cited by 206
Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells
Kapitza, S., Pongratz, M., Jakupec, M. A., Heffeter, P., Berger, W., Lackinger, L., Keppler, B. K., & Marian, B. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0617-0 · Cited by 200
Ware, D. C., Palmer, B. D., Wilson, W. R., & Denny, W. A. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00065a006 · Cited by 193
Induction of mitochondrial permeability transition by auranofin, a Gold(I)‐phosphine derivative
Rigobello, M. P., Scutari, G., Boscolo, R., & Bindoli, A. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704823 · Cited by 178
Rhodium and its compounds as potential agents in cancer treatment
Katsaros, N., & Anagnostopoulou, A. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00222-0 · Cited by 165
Jakupec, M. A., Reisner, E., Eichinger, A., Pongratz, M., Arion, V. B., Galanski, M. S., Hartinger, C. G., & Keppler, B. K. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0490742 · Cited by 164
Hart, M. M., & Adamson, R. H. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.7.1623 · Cited by 161
Rigobello, M. P., Scutari, G., Folda, A., & Bindoli, A. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.09.038 · Cited by 158
Rossi, M. (2004) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557043487565 · Cited by 147
Anti-proliferative activity and mechanism of action of titanocene dichloride
Christodoulou, C., Eliopoulos, A. G., Young, L. S., Hodgkins, L., Ferry, D. R., & Kerr, D. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.352 · Cited by 145
Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A
Vacca, A., Bruno, M., Boccarelli, A., Coluccia, M., Ribatti, D., Bergamo, A., Garbisa, S., Sartor, L., & Sava, G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600176 · Cited by 140
A Series of Unconjugated Ferrocenyl Phenols: Prospects as Anticancer Agents
Hillard, E. A., Vessières, A., Bideau, F. L., Plażuk, D., Spera, D., Huché, M., & Jaouen, G. (2006) · ChemMedChem · doi:10.1002/cmdc.200500035 · Cited by 138
Kapitza, S. B., Jakupec, M. A., Uhl, M., Keppler, B. K., & Marian, B. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.002 · Cited by 119
Inhibitory effects of a new oral gold compound on hela cells
Simon, T. M., Kunishima, D. H., Gj, V., & LORBER, A. (1979) · Cancer · Cited by 116
Toxicity and Antitumor Activity of Gallium Nitrate and Periodically Related Metal Salts2 2
Hart, M. M., Smith, C. F., Yancey, S. T., & Adamson, R. H. (1971) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/47.5.1121 · Cited by 97
Deponte, M., Urig, S., Arscott, L. D., Fritz‐Wolf, K., Réau, R., Herold‐Mende, C. C., Končarević, S., Meyer, M., Davioud–Charvet, E., Ballou, D. P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412519200 · Cited by 93
Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers
Morbidelli, L., Donnini, S., Filippi, S., Luigi Messori, A., Piccioli, F., Orioli, P., Sava, G., & Ziche, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600906 · Cited by 92
Piccioli, F., Sabatini, S., Luigi Messori, A., Orioli, P., Hartinger, C. G., & Keppler, B. K. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.04.002 · Cited by 83
Guo, M., Guo, Z., & Sadler, P. J. (2001) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s007750100248 · Cited by 82
Ahn, G., Botting, K. J., Patterson, A. V., Ware, D. C., Tercel, M., & Wilson, W. R. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.03.007 · Cited by 81
Dinitrosyl-iron triggers apoptosis in Jurkat cells despite overexpression of Bcl-2
Kleschyov, A. L., Strand, S., Schmitt, S., Gottfried, D., Skatchkov, M. P., Sjakste, N., Daiber, A., Umansky, V., & Münzel, T. F. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.12.001 · Cited by 77
Hofheinz, R., Dittrich, C., Jakupec, M. A., Drescher, A., Jaehde, U., Gneist, M., von Keyserlingk, N. G., Keppler, B. K., & Hochhaus, A. (2005) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp43590 · Cited by 64
Interactions of gold coordination complexes with DNA
Mirabelli, C. K., Sung, C.-M., Zimmerman, J. P., Hill, D. T., Mong, S., & Crooke, S. T. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90106-1 · Cited by 61
Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds
Engman, L., McNaughton, M., Gajewska, M., Kumar, S., Birmingham, A., & Powis, G. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200606000-00007 · Cited by 54
Antineoplastic drugs that interfere with iron metabolism in cancer cells
Head, J. F., Wang, F., & Elliott, R. L. (1997) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(96)00010-6 · Cited by 53
Ott, I., Koch, T., Shorafa, H., Bai, Z., Poeckel, D., Steinhilber, D., & Gust, R. (2005) · Organic & Biomolecular Chemistry · doi:10.1039/b504294c · Cited by 52
Self-citationSmith, P. F., Hoke, G. D., Alberts, D. W., Bugelski, P. J., Lupo, S., Mirabelli, C. K., & Rush, G. F. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23520-0 · Cited by 51
Ware, D. C., Palmer, H. R., Brothers, P. J., Rickard, C. E. F., Wilson, W. R., & Denny, W. A. (1997) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(97)00090-1 · Cited by 49
Ahn, G., Ware, D. C., Denny, W. A., & Wilson, W. R. (2004) · Radiation Research · doi:10.1667/rr3229 · Cited by 42
The mechanism of acute cytotoxicity of triethylphosphine gold(I) complexes
Hoke, G. D., Rush, G. F., & Mirabelli, C. K. (1989) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(89)90110-5 · Cited by 20
A Phase II Trial of Gallium Nitrate in Patients with Androgen-Metastatic Prostate Cancer
Senderowicz, A. M., Reid, R., Headlee, D. J., Abornathy, T., Horti, J., Lush, R. M., Reed, E., Figg, W. D., & Sausville, E. A. (1999) · Urologia Internationalis · doi:10.1159/000030430 · Cited by 20
Cited by
On the medicinal chemistry of gold complexes as anticancer drugs
Ott, I. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.019 · Cited by 825
Self-citationCopper in diseases and treatments, and copper‐based anticancer strategies
Tisato, F., Marzano, C., Porchia, M., Pellei, M., & Santini, C. (2010) · Medicinal Research Reviews · doi:10.1002/med.20174 · Cited by 797
Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs
Liu, W., & Gust, R. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35314h · Cited by 762
Self-citationvan Rijt, S. H., & Sadler, P. J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.003 · Cited by 592
In Situ Imaging of Metals in Cells and Tissues
McRae, R., Bagchi, P., Sumalekshmy, S., & Fahrni, C. J. (2009) · Chemical Reviews · doi:10.1021/cr900223a · Cited by 570
Metadata
- Authors
- Ott, I., & Gust, R.
- Venue
- Archiv der Pharmazie
- Publisher
- Wiley
- Published
- 2007-03
- Volume
- 340
- Issue
- 3
- Pages
- 117-126
- ISSN
- 0365-6233 (ISSN-L)
- 1521-4184
- OpenAlex
- W2099473254
- Cited by
- 609
- References
- 58
- FWCI
- 10.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.